Isis Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc.

Novartis Ag

Sarepta Therapeutics, Inc.

Other

Northwestern University

Ciba-geigy Ag

Ionis Pharmaceuticals, Inc.

Novartis Corporation

South Alabama Medical Science Foundation

Antisense Therapeutics Limited

Ercole Biotech, Inc.

Nicholas M Dean

C Frank Bennett

Robert McKay

Brett P Monia

Niall O'Donnell

J Gordon Foulkes

Kenneth W Dobie

Eric G Marcusson

Karl-Heinz Altmann

William A Gaarde

Pamela S Nero

Loren J Miraglia

Brian J Nickoloff

Susan M Frier

Lex M Cowsert

Pierre Martin

Brenda F Baker

Ryszard M Kole

Timothy A Vickers

Casey Kopczynski

Richard Eric Honkanen

Russell T Boggs

QingQing Zhang

Thomas Geiger

Muthiah Manoharan

Susan M Freier

Phillip Dan Cook

Jacqueline R Wyatt

James G Karras

Clarence Frank Bennett

Doriano Fabbro

Glenn D Hoke

Elizabeth J Ackermann

Erich Koller

Gregory E Hardee

Susan F Murray

Ranjan Perera

Thomas A Mustoe

Christopher John Wraight

Helmut Mett

Robert Haner

George Arthur Werther

Ming-Yi Chiang

Edgardo Baracchini, Jr

F Andrew Dorr

Vivian Qingqing Zhang

Leroy Young

Jon T Holmlund

Mark Jewell

Cristopher John Wraight

Seongjoon Koo

Lincoln Krochmal

Zol Kryger

Marcel Muller

Mark Sisco

Casey C Kopczynski

Niall O`DONNELL

This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.

Antisense oligonucleotides directed against connective tissue growth factor and uses thereof

This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described.

Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)

Disclosed herein are compounds, compositions and methods for modulating splicing of a selected target mRNA. Further provided are uses of the disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Methods of enhancing cellular uptake, modulating tissue distribution and enhancing pharmacological activity of RNase H-independent antisense oligonucleotides are also provided.

Chimeric oligomeric compounds for modulation of splicing

This invention provides a method for reducing hypertropic scarring resulting from dermal wound healing in a subject in need which comprises administering to the subject an antisense oligonucleotide which inhibits expression of connective tissue growth factor (CTGF) in an amount effective to inhibit expression of CTGF and thereby reduce hypertrophic scarring.

Method for reducing scarring during wound healing using antisense compounds directed to CTGF

Methods for inhibiting expression of connective tissue growth factor

Antisense compounds, compositions and methods are provided for modulating the expression of MyD88. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MyD88. Methods of using these compounds for modulation of MyD88 expression and for treatment of diseases associated with expression of MyD88 are provided.

Modification of MYD88 splicing using modified oligonucleotides

Disclosed herein are compounds, compositions and methods for modulating the expression of HBXIP in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.

Compositions and their uses directed to HBXIP

Modification of MyD88 splicing using modified oligonucleotides

The present invention provides compounds, compositions, and methods for identification of motifs within regulatory regions of genes involved in adipogenesis and adipocyte differentiation. Compounds and compositions are provided for modulating expression of nuclear receptor/transcription factor-regulated genes. Methods for modulating the function of PPAR-&#x3b3; as well as PPAR-&#x3b3;-regulated gene promoters, and methods of using oligomeric compounds for diagnosis and treatment of diseases such as obesity and diabetes are also provided.

Identification of novel pathways, genes and promoter motifs regulating adipogenesis

Compounds, compositions and methods are provided for modulating the expression of Tudor-SN. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Tudor-SN. Methods of using these compounds for modulation of Tudor-SN expression and for diagnosis and treatment of diseases and conditions associated with expression of Tudor-SN are provided.

Modulation of Tudor-SN expression

The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.

Modulation of insulin like growth factor I receptor expression

Compounds, compositions and methods are provided for modulating the expression of Aurora B. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Aurora B. Methods of using these compounds for modulation of Aurora B expression and for diagnosis and treatment of diseases and conditions associated with expression of Aurora B are provided. Also provided are methods of using these compounds to modulate the growth of cancer cells, including p53-deficient cancer cells.

Modulation of Aurora B expression

Growing community of inventors

Olivenhain, CA, United States of America

Nicholas M Dean